COVID-19 and Endocan Levels

Balta, Şevket

doi:10.1177/0003319720965817

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is growing evidence about the value of endocan in COVID-19 in the literature. The etiopathology of COVID-19-related cardiovascular (CV) disease could involve endothelial dysfunction [ 13 ]. Endocan was recently identified as a marker of endothelial dysfunction and potentially as an immune-inflammatory marker that may be associated with CV events [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients

Chenevier‐Gobeaux

Ducastel

Méritet

et al. 2022

JCM

View full text Add to dashboard Cite

(1) Background: Endocan is a marker of endothelial dysfunction that may be associated with thrombotic events. The aim of the study was to investigate the performance of endocan as a marker of thrombotic events in COVID-19 patients. (2) Methods: We measured endocan in plasma from 79 documented COVID-19 patients classified according to disease severity (from mild to critical). Thrombotic events were recorded. (3) Results: Endocan concentrations at admission were significantly increased according to COVID-19 severity. Levels of endocan were significantly increased in patients experiencing thrombotic events in comparison with those without (16.2 (5.5–26.7) vs. 1.81 (0.71–10.5) ng/mL, p < 0.001). However, endocan concentrations were not different between pulmonary embolism and other thrombotic events. The Receiver Operating Characteristic (ROC) analysis for the identification of thrombotic events showed an area under the ROC curve (AUC) of 0.776 with an optimal threshold at 2.83 ng/mL (93.8% sensitivity and 54.7% specificity). When combining an endocan measurement with D-dimers, the AUC increased to 0.853. When considering both biomarkers, the Kaplan–Meier survival curves showed that the combination of endocan and D-dimers better discriminated patients with thrombotic events than those without. The combination of D-dimers and endocan was independently associated with thrombotic events. (4) Conclusions: Endocan might be a useful and informative biomarker to better identify thrombotic events in COVID-19 patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients

Chenevier‐Gobeaux

Ducastel

Méritet

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

May endocan be a new biomarker in the diagnosis of endometriosis?

Senocak

Yapça

Yılmaz

et al. 2022

Journal of Gynecology Obstetrics and Human Reproduction

View full text Add to dashboard Cite

COVID-19 and Inflammatory Markers

Balta

2022

CVP

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19), causes mild illness to serious infection with lung involvement, thrombosis and other complications potentially resulting in fatal outcome. Recognised inflammatory biomarkers play important roles in the management of patients with COVID-19; for example, diagnosis, follow-up, assessment of treatment response and risk stratification. Inflammatory markers in COVID-19 disease were analysed in two categories. Well-known inflammatory markers included complete blood count, C-reactive protein, albumin, cytokines and erythrocyte sedimentation rate. Asymmetric dimethylarginine, endocan, pentraxin 3, serum amyloid A, soluble urokinase plasminogen activator receptor, total oxidant status and total antioxidant status, galectin-3 were considered among the emerging inflammatory markers. This brief narrative review assesses the relationship between these inflammatory markers and COVID-19 infection.

show abstract

COVID-19 and Endocan Levels

Cited by 3 publications

References 9 publications

Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients

Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients

May endocan be a new biomarker in the diagnosis of endometriosis?

COVID-19 and Inflammatory Markers

Contact Info

Product

Resources

About